222 related articles for article (PubMed ID: 16082021)
1. Biopharmaceutical proteins: opportunities and challenges.
Birch JR; Onakunle Y
Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
[No Abstract] [Full Text] [Related]
2. Editorial: biopharmaceutical technologies.
Jungbauer A
Biotechnol J; 2007 Jun; 2(6):647. PubMed ID: 17570696
[No Abstract] [Full Text] [Related]
3. Biopharmaceutical drug discovery using novel protein scaffolds.
Gill DS; Damle NK
Curr Opin Biotechnol; 2006 Dec; 17(6):653-8. PubMed ID: 17055245
[TBL] [Abstract][Full Text] [Related]
4. The farmyard drug store.
Nature; 2006 Sep; 443(7107):16-7. PubMed ID: 16957702
[No Abstract] [Full Text] [Related]
5. Biopharma in Piedmont, Italy.
Sakariassen KS
Nat Rev Drug Discov; 2005 Jun; 4(6):519. PubMed ID: 15959953
[No Abstract] [Full Text] [Related]
6. The state of biopharmaceutical manufacturing.
Molowa DT; Mazanet R
Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
[TBL] [Abstract][Full Text] [Related]
7. Biopharmaceuticals in China.
Hu X; Ma Q; Zhang S
Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
[TBL] [Abstract][Full Text] [Related]
8. Flexibility--the guiding principle for antibody manufacturing.
Carson KL
Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
[TBL] [Abstract][Full Text] [Related]
9. Biopharmaceutical production in plants: problems, solutions and opportunities.
Gomord V; Chamberlain P; Jefferis R; Faye L
Trends Biotechnol; 2005 Nov; 23(11):559-65. PubMed ID: 16168504
[TBL] [Abstract][Full Text] [Related]
10. Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers.
Lakhdar K; Farid SS; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2006; 22(6):1630-6. PubMed ID: 17137311
[TBL] [Abstract][Full Text] [Related]
11. Introduction to current and future protein therapeutics: a protein engineering perspective.
Carter PJ
Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
[TBL] [Abstract][Full Text] [Related]
12. Medium term planning of biopharmaceutical manufacture using mathematical programming.
Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of biopharmaceuticals: current issues.
Strohl WR; Knight DM
Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
[No Abstract] [Full Text] [Related]
14. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
15. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
Sivakumar G
Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
[TBL] [Abstract][Full Text] [Related]
16. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
Thomsen MK
Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
[No Abstract] [Full Text] [Related]
17. HTS technologies in biopharmaceutical discovery.
Wu G; Doberstein SK
Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
[TBL] [Abstract][Full Text] [Related]
18. The challenges of product- and process-related impurities to an evolving biopharmaceutical industry.
Bracewell DG; Smales CM
Bioanalysis; 2013 Jan; 5(2):123-6. PubMed ID: 23330553
[No Abstract] [Full Text] [Related]
19. Continuous bioprocessing: the real thing this time? 10(th) Annual bioProcessUK Conference, December 3-4, 2013, London, UK.
Farid SS; Thompson B; Davidson A
MAbs; 2014; 6(6):1357-61. PubMed ID: 25484060
[TBL] [Abstract][Full Text] [Related]
20. Advancing protein therapeutics: current challenges in protein therapeutics -- CHI's Second Annual Conference.
He M
IDrugs; 2006 Mar; 9(3):177-8. PubMed ID: 16523380
[No Abstract] [Full Text] [Related]
[Next] [New Search]
